TipRanks
Pharming Group (DE:PHGN)
XETRA:PHGN
Germany Market
PHGN
Pharming Group
RESEARCH TOOLSreports

Pharming Group (PHGN) Stock News & Sentiment

5 Followers
Pharming Group: Buy Rating Maintained and Strategy Intact Despite Surprise CEO Departure; Price Target Reaffirmed at $38
Premium
Ratings
Pharming Group: Buy Rating Maintained and Strategy Intact Despite Surprise CEO Departure; Price Target Reaffirmed at $38
6d ago
PHAR
Pharming Group Installs Interim Co-CEOs as Board and CEO Part Ways Over Strategy
Premium
Company Announcements
Pharming Group Installs Interim Co-CEOs as Board and CEO Part Ways Over Strategy
7d ago
Pharming Wins FDA Priority Review for Lower-Dose Joenja in Younger APDS Patients
Premium
Company Announcements
Pharming Wins FDA Priority Review for Lower-Dose Joenja in Younger APDS Patients
11d ago
Pharming posts positive Phase II data for leniolisib in rare immune disorders
Premium
Company Announcements
Pharming posts positive Phase II data for leniolisib in rare immune disorders
14d ago
Pharming wins FDA nod to extend Joenja use to younger APDS children
Premium
Company Announcements
Pharming wins FDA nod to extend Joenja use to younger APDS children
25d ago
Pharming Group Steps Up Investor Outreach With September Conference Lineup
Premium
Company Announcements
Pharming Group Steps Up Investor Outreach With September Conference Lineup
27d ago
Pharming launches Joenja in Japan, first market to treat APDS children from age four
Premium
Company Announcements
Pharming launches Joenja in Japan, first market to treat APDS children from age four
2M ago
More DE:PHGN News >

PHGN News on the Web

Pharming announces ‘positive’ Phase 2 topline data for leniolisib in PIDs
TipRanks News
Neutral
Pharming launches Joenja in Japan, first market to treat APDS children from age four
TipRanks News
Bullish
Buy Rating Reaffirmed on Joenja’s European Expansion and Pediatric FDA Catalyst; $37 Price Target Maintained
TipRanks News
Bullish
Pharming: Profitable Core, Advancing Pipeline Underpin Buy Rating and Maintained $37 Price Target
TipRanks News
Bullish
Pantginis Reiterates Buy on Pharming as Joenja’s Global Expansion Advances; $37 Price Target Maintained
TipRanks News
Bullish
Pharming’s Joenja granted marketing authorization by European Commission
TipRanks News
Bullish
Pharming initiated with a Buy at Canaccord on growth potential
TipRanks News
Bullish
Pharming initiated with a Buy at Canaccord
TipRanks News
Neutral

News Score - Last 7 Days

Neutral
DE:PHGN
Sector Average
Media Buzz
This Week1 articles
Weekly Average2.5 articles
News Sentiment
This Week100%
Sector Average91%
See how Bullish or Bearish a stock is based on its recent media coverage.

This score is generated using a formula that combines Media Buzz and News Sentiment.

Media Coverage Analysis

The historical news coverage of this asset in the last three months.

FAQ

What is DE:PHGN’s Media Buzz Sentiment?
1 articles about DE:PHGN were published this week. In an average week, 2.5 articles are published.
    What is DE:PHGN’s weekly average amount of articles?
    In an average week, 2.5 articles about DE:PHGN are published.
      What is DE:PHGN’s News Sentiment?
      100% of articles about DE:PHGN were positive this week, compared to its sector average of 91%.
        Healthcare Stocks that are Trending in the News
        XERSXeris Pharmaceuticals
        QTTBQ32 Bio
        ABTAbbott Laboratories
        GMABGenmab
        BAYRYBayer
        Showing the stocks with the most bullish news sentiment over the past week